Join our annual Boston Oncology Drug Discovery symposium, this year focusing on the novel technologies and trends driving new cancer therapies. Cancer research is constantly being reinvented, as we learn more
Join our annual Boston Oncology Drug Discovery symposium, this year focusing on the novel technologies and trends driving new cancer therapies.
Cancer research is constantly being reinvented, as we learn more about human and tumor biology and how they interact with and influence each other. With sustained innovation in preclinical oncology tools and therapeutic approaches, our improved understanding can continue to be translated into new targeted agents and immunotherapies with improved patient benefits.
The symposium will bring together preclinical oncology and immuno-oncology R&D teams from biotech and pharmaceutical companies to facilitate cross discipline discussions on current techniques, and how you can move forward with future approaches.
Discussion Topics Include
- Optimizing TIL profiling to investigate relationships between I/O model tumor microenvironment and immunotherapy treatment outcomes
- Novel targets in DNA repair pathways, including for PARP inhibitors
- The evolution of current preclinical models such as PDX for evaluation of next generation therapies
Presentation & Speakers
Senior Director, I/O Discovery and Translational Biology, BioXcel Therapeutics
Senior Vice President, Global Scientific Research and Innovations, Crown Bioscience
Senior Director, Research and Early Development, TESARO
Associate Director, Global Biomarker Core, Crown Bioscience
Associate Director, Preclinical Oncology, Dicerna Pharmaceuticals
All Day (Tuesday)